PrEP Implementation and Persistence in a County Health Department Setting in Atlanta, GA.


Journal

AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133

Informations de publication

Date de publication:
Oct 2019
Historique:
pubmed: 31 8 2019
medline: 7 11 2019
entrez: 31 8 2019
Statut: ppublish

Résumé

For marginalized populations, county health departments may be important PrEP access points; however, there are little data on successful PrEP programs at these venues outside of incentivized demonstration projects. Therefore, we implemented an open-access, free PrEP clinic at a county health department in Atlanta, GA to promote PrEP uptake among high-risk clients. The Fulton County Board of Health PrEP clinic launched in October 2015, and eligible clients who expressed interest initiated PrEP and attended follow-up visits per CDC guidelines. Clients engaged in quarterly follow-up and seen within the last 6 months were defined as "persistent", whereas clients with a lapse in follow-up of > 6 months were defined as "not persistent." Factors associated with PrEP persistence were assessed with unadjusted odds ratios. Between October 2015 and June 2017, 399 clients were screened for PrEP, almost all were eligible [392/399 (98%)]; however, 158/392 (40%) did not return to start PrEP after screening. Of 234 patients, 216 (92%) received a prescription for PrEP. As of June 2017, only 69/216 (32%) clients remained persistent in PrEP care, and the only evaluated factor significantly associated with PrEP persistence was age ≥ 30 years (OR 1.86, 95% CI 1.02, 3.42). Implementation of PrEP in the county health department setting is feasible; however, we have identified significant challenges with PrEP uptake and persistence in our setting. Further research is needed to fully understand mediators of PrEP persistence and inform interventions to optimize health department-based PrEP services.

Identifiants

pubmed: 31468296
doi: 10.1007/s10461-019-02654-x
pii: 10.1007/s10461-019-02654-x
pmc: PMC6800647
mid: NIHMS1538566
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

296-303

Subventions

Organisme : NIAID NIH HHS
ID : K23 AI108335
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI114407
Pays : United States
Organisme : NIH HHS
ID : K23AI108335
Pays : United States
Organisme : NIH HHS
ID : K23AI114407
Pays : United States

Références

JAMA. 2018 Dec 11;320(22):2304
pubmed: 30535224
J Int AIDS Soc. 2016 Jun 13;19(1):20903
pubmed: 27302837
JMIR Public Health Surveill. 2019 Feb 04;5(1):e12405
pubmed: 30714945
Ann Epidemiol. 2018 Dec;28(12):841-849
pubmed: 29983236
Lancet HIV. 2018 Mar;5(3):e136-e145
pubmed: 29467098
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):540-546
pubmed: 27851714
Ann Epidemiol. 2018 Dec;28(12):858-864
pubmed: 30406756
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):21-29
pubmed: 27632233
J Int AIDS Soc. 2019 Feb;22(2):e25252
pubmed: 30775846
AIDS Behav. 2018 Apr;22(4):1096-1099
pubmed: 29243109
Clin Infect Dis. 2018 Jul 2;67(2):283-287
pubmed: 29506057
Soc Sci Med. 2017 Jan;172:115-123
pubmed: 27866750
Obstet Gynecol Surv. 2015 Apr;70(4):284-90
pubmed: 25900528
Int J STD AIDS. 2016 Sep;27(10):873-81
pubmed: 26384947
AIDS. 2017 Mar 13;31(5):731-734
pubmed: 28060019
Curr HIV/AIDS Rep. 2019 Aug;16(4):259-269
pubmed: 31177363
J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):62-69
pubmed: 29771790
AIDS Patient Care STDS. 2014 Dec;28(12):635-42
pubmed: 25295393
MMWR Morb Mortal Wkly Rep. 2018 Oct 19;67(41):1147-1150
pubmed: 30335734
J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):250-258
pubmed: 28708811
J Virus Erad. 2016 Jul 01;2(3):149-55
pubmed: 27482454
PLoS One. 2017 Feb 21;12(2):e0172354
pubmed: 28222118
AIDS Patient Care STDS. 2015 Feb;29(2):102-10
pubmed: 25513954
PLoS One. 2018 Jul 25;13(7):e0200338
pubmed: 30044820
AIDS Care. 2017 Jul;29(7):866-869
pubmed: 28147704
Clin Infect Dis. 2015 Nov 15;61(10):1590-7
pubmed: 26270691
JAMA Intern Med. 2016 Jan;176(1):75-84
pubmed: 26571482
Clin Infect Dis. 2016 Sep 1;63(5):672-7
pubmed: 27282710
Am J Public Health. 2016 Oct;106(10):e2-3
pubmed: 27626355
Ann Epidemiol. 2017 Apr;27(4):238-243
pubmed: 28325538

Auteurs

Charlotte-Paige Rolle (CP)

Orlando Immunology Center, 1707 North Mills Avenue, Orlando, 32803, FL, USA. crolle@emory.edu.
Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA. crolle@emory.edu.

Udodirim Onwubiko (U)

Fulton County Board of Health, Atlanta, GA, USA.

Jennifer Jo (J)

Emory University School of Medicine, Atlanta, GA, USA.

Anandi N Sheth (AN)

Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.

Colleen F Kelley (CF)

Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.

David P Holland (DP)

Fulton County Board of Health, Atlanta, GA, USA.
Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH